EPISODE · Oct 24, 2024 · 10 MIN
Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'
Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.
NOW PLAYING
Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m